Compare BTBD & ALZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BTBD | ALZN |
|---|---|---|
| Founded | 1987 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1M | 7.5M |
| IPO Year | 2019 | 2021 |
| Metric | BTBD | ALZN |
|---|---|---|
| Price | $1.75 | $1.71 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $28.00 |
| AVG Volume (30 Days) | 36.9K | ★ 83.8K |
| Earning Date | 05-15-2026 | 03-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 76.77 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $14,823,472.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.03 | $0.84 |
| 52 Week High | $2.48 | $2.68 |
| Indicator | BTBD | ALZN |
|---|---|---|
| Relative Strength Index (RSI) | 76.25 | 65.28 |
| Support Level | $1.53 | $1.41 |
| Resistance Level | $1.67 | $2.25 |
| Average True Range (ATR) | 0.08 | 0.11 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 90.91 | 90.32 |
BT Brands Inc operates and owns a fast-food restaurant called Burger Time. Its offerings include a variety of burgers and other affordable items, including sides and soft drinks. The company owns and operates Keegan's Seafood Grille (Keegan's), a dine-in restaurant located in Florida; Pie In The Sky Coffee and Bakery (PIE), located in Massachusetts; and Schnitzel Haus, a German-themed restaurant located in Florida. The company's revenues are derived from the sale of food and beverages at its restaurants.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's disease. The Company has two therapeutic drug candidates, AL001 and ALZN002. Its pipeline consists of AL001, a patented ionic cocrystal technology delivering lithium through a therapeutic combination of lithium, proline and salicylate; and ALZN002, a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's disease.